Brooks Laboratories Ltd

Brooks Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 14 August 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 02 September 2026, providing investors with the latest insights into the company’s fundamentals, valuation, financial trends, and technical outlook.

At Rs 69.28, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Brooks Laboratories Ltd locked at its upper circuit of 4.99% on 28 Aug 2026, with buyers queuing and no sellers willing to part with shares.

At Rs 65.99, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Brooks Laboratories Ltd locked at its upper circuit of 5.0% on 27 Aug 2026, with buyers queuing and no sellers willing to part with shares.

Brooks Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 14 August 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 22 August 2026, providing investors with the latest insights into the company’s performance and outlook.

At Rs 62.32, sellers were still queuing — but there were no buyers willing to take the other side. Brooks Laboratories Ltd locked at its lower circuit of 5.0% on 14 Aug 2026, with unfilled sell orders and a frozen price, signalling a pronounced imbalance in supply and demand.

Brooks Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has reported a marked deterioration in its financial performance for the quarter ended June 2026. The company’s financial trend has shifted from flat to negative, with key profitability metrics plunging and the stock price reflecting investor concerns amid broader market pressures.

At Rs 65.60, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Brooks Laboratories Ltd locked at its upper circuit of 5% on 13 Aug 2026, with buyers queuing and no sellers willing to part with shares.

At Rs 62.48, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Brooks Laboratories Ltd locked at its upper circuit of 5% on 12 Aug 2026, with buyers queuing and no sellers willing to part with shares.

Brooks Laboratories Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 10 August 2026, driven primarily by a shift in technical indicators despite ongoing challenges in financial performance and valuation metrics. This nuanced change reflects a cautious optimism in the stock’s near-term price action while acknowledging persistent fundamental weaknesses.

Brooks Laboratories Ltd has been downgraded from a Sell to a Strong Sell rating as of 5 August 2026, reflecting deteriorating technical indicators and persistent fundamental weaknesses. The pharmaceutical micro-cap’s latest quarterly results and long-term financial trends have failed to inspire confidence, while its technical profile has shifted further into bearish territory. This comprehensive analysis explores the four key parameters—Quality, Valuation, Financial Trend, and Technicals—that have driven this decisive rating change.

Brooks Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 08 July 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 31 July 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

At Rs 63.00, Brooks Laboratories Ltd found itself trapped at its lower circuit on 24 Jul 2026, with a 4.52% decline marking the maximum loss permitted by the 5% price band. Despite sellers lining up to exit, there were no buyers willing to absorb the supply, resulting in a frozen price and unfilled sell orders throughout the session.

Brooks Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 08 July 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 July 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

Brooks Laboratories Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 8 July 2026, driven primarily by a significant improvement in its valuation metrics. Despite persistent challenges in financial performance and technical indicators, the company’s valuation grade has shifted from fair to very attractive, prompting a reassessment of its investment appeal within the Pharmaceuticals & Biotechnology sector.

Brooks Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen a significant shift in its valuation parameters, moving from a fair to a very attractive rating. Despite recent share price declines and underperformance relative to the Sensex, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now present compelling entry points compared to both its historical averages and peer group valuations.

At Rs 69.52, Brooks Laboratories Ltd found itself locked at its lower circuit limit of 4.81% on 08 Jul 2026, with persistent selling pressure overwhelming demand and leaving unfilled supply at the floor price.